<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6453">
  <stage>Registered</stage>
  <submitdate>21/04/2017</submitdate>
  <approvaldate>21/04/2017</approvaldate>
  <nctid>NCT03136926</nctid>
  <trial_identification>
    <studytitle>Screening Anti-Fungal Exposure in Intensive Care Units</studytitle>
    <scientifictitle>An International, Multi-centre Prospective Pharmacokinetic Evaluation of Antifungal Drug Exposure in Intensive Care Unit Patients Receiving Conventional Dosing Regimens</scientifictitle>
    <utrn />
    <trialacronym>SAFE-ICU</trialacronym>
    <secondaryid>SAFE-ICU Protocol V2</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Antifungal Agents</healthcondition>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Probability of therapeutic target attainment - Probability of attainment of therapeutic target associated with optimal efficacy will be determined by measuring the ratio of area under the concentration-time curve (AUC) to the minimum inhibitory concentration (MIC).</outcome>
      <timepoint>Seven days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mortality - 30-day mortality</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age = 18

          -  Critically ill patients requiring ICU care

          -  Receiving enteral or intravenous therapy of antifungal of interest (triazole,
             echinocandin, amphotericin) including prophylaxis indication and antifungal therapy
             started in another unit (wards, operating room) for the same infectious episode

          -  Availability of suitable intravenous/intra-arterial access to facilitate sample
             collection

          -  Written informed consent has been obtained from the patient or their next of kin
             (according to local regulatory statements for ethical conduct of research at each
             study site)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Aged &lt; 18 years of age

          -  Pregnancy

          -  Consent not obtained (according to local regulatory statements for ethical conduct of
             research at each study site)

          -  Diagnosis with human immunodeficiency virus or hepatitis B or C or tuberculosis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>The Royal Melbourne Hospital - Melbourne</hospital>
    <postcode>4029 - Brisbane</postcode>
    <postcode>3050 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Lodelinsart</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Mons</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Ottignies</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Joensuu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Lahti</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nimes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pringy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong SAR</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Johor</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kelantan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Pahang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Serdang</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisbon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Porto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Vila Franca de Xira</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of Queensland</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Adequate antifungal therapy is a critical determinant of survival in patients admitted to an
      Intensive Care Unit (ICU) with suspected or proven fungal infections. Critical illness can
      alter the way human body handles antifungal agents, i.e. how the drugs are distributed in the
      body and removed from the body. Consequently, these changes can increase the risk of
      inappropriate antifungal exposure that may lead to adverse consequence on patients' outcome.
      Developing an evidence-based antifungal dosing guideline is of global significance and should
      be considered a priority to improving clinical outcomes for patients receiving antifungal
      agents

      The aim of the SAFE-ICU Study is to develop optimised antibiotic dosing guidelines for ICU
      patients with life-threatening infections that account for patient characteristics. This will
      be achieved through completion of the following aims:

      i) Describe detailed demographic, clinical and plasma antibiotic concentration-time data in a
      large ICU patient cohort; ii) Perform a robust statistical analysis of the data collected in
      Aim 1 to develop an enhanced preliminary prediction algorithm for antifungal dosing.

      This is a multi-national study and will enrol ICU patients who are prescribed an antifungal
      agent (fluconazole, voriconazole, posaconazole, isavuconazole, caspofungin, anidulafungin,
      micafungin or amphotericin B). A minimum of 12 patients per drug will be enrolled across at
      least 15 countries and up to 80 ICUs.

      Eligible patients are those admitted to the ICU, who are prescribed an antifungal agent
      (fluconazole, voriconazole, posaconazole, isavuconazole, caspofungin, anidulafungin,
      micafungin or amphotericin B). Blood samples will be taken to measure drug concentration.
      Sampling will occur on two occasions, first during study days 1-3 and then a second time
      between days 4-7, each over an 8-24 hour period. Blood samples will be taken from a vascular
      access device already inserted for ICU patient care. Abdominal samples from abdominal
      indwelling drains already inserted peri operatively will also be collected on these two
      occasions in the subgroup of patients with intra-abdominal infection. Data on infection,
      various blood tests and patient specific data will be collected using a structured case
      report form (CRF). Patients will also be followed up 30 days after enrolment into the study
      to evaluate 30-day mortality.

      Collected samples will be frozen and stored locally and then shipped in large batches for
      processing at Burns Trauma and Critical Care Research Centre, The University of Queensland,
      Australia. Data analysis for development of antifungal dosing algorithms will also be
      undertaken at The University of Queensland, Australia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03136926</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jason A Roberts, PhD</name>
      <address>The University of Queensland</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Fekade B Sime, PhD</name>
      <address />
      <phone>+61 412 181 027</phone>
      <fax />
      <email>f.sime@uq.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>